China
Africa
Explore chapters and articles related to this topic
Antiepileptic Drugs
Published in Sahab Uddin, Rashid Mamunur, Advances in Neuropharmacology, 2020
Gabapentin and pregabalin have shown evidence in improving diabetic neuropathy and postherpetic neuralgia. Pregabalin is effective in central neuropathic pain and fibromyalgia. Phenytoin and valproic have shown no evidence in decreasing pain. Similarly, carbamazepine, oxcarbazepine, topiramate, lamotrigine, and lacosamide have either no or low quality evidence to be effective in reducing pain (Wiffen et al., 2013).
Disorders
Published in Jonathan P Rogers, Cheryl CY Leung, Timothy RJ Nicholson, Pocket Prescriber Psychiatry, 2019
Jonathan P Rogers, Cheryl CY Leung, Timothy RJ Nicholson
Pregabalin can be started immediately at a treatment dose of 150 mg daily in two to three divided doses. If required, it can be increased in steps of 150 mg after 7 days up to 600 mg daily total. However, many patients will benefit from more gradual dose titration.
Psychopharmacology and mental health
Published in Chambers Mary, Psychiatric and mental health nursing, 2017
The main side effects associated with the use of pregabalin are blurred vision, dizziness, nausea and sleepiness. Due to an increased risk of seizures on sudden withdrawal, pregabalin is always withdrawn gradually.
Increase in pregabalin recreational use in adolescents in France
Published in Clinical Toxicology, 2021
Laurene Dufayet, Weniko Care, Sylvie Deheul, Hervé Laborde-Casterot, Patrick Nisse, Jerome Langrand, Dominique Vodovar
Symptoms associated with the recreational use of pregabalin are consistent with those previously described in pregabalin poisonings. Pregabalin only poisoning usually causes mild sedation and uncommonly coma or seizures [5–7]. Co-ingestion of other sedating toxicants, especially benzodiazepine and opioids seems to lead more frequently to coma and has been associated with fatalities [5,8,9]. In our study, eight adolescents developed severe symptoms. Unfortunately, the data were too scarce to draw any conclusion about the role of the alleged ingested dose of pregabalin or the co-ingested substances in the onset of the symptoms. As none of the patients benefited from toxicological analysis, no correlation between the concentration of pregabalin and the severity of the symptoms was possible.
An update on the pharmacological management of pain in patients with multiple sclerosis
Published in Expert Opinion on Pharmacotherapy, 2020
Clara G. Chisari, Eleonora Sgarlata, Sebastiano Arena, Emanuele D’Amico, Simona Toscano, Francesco Patti
Pregabalin is an anticonvulsivant medication used to treat epilepsy, neuropathic pain, fibromyalgia, restless leg syndrome, and generalized anxiety disorder. Pregabalin acts as a gabapentinoid, inhibiting several calcium channels [51]. In regards to MS pain, pregabalin has been used in an open-label pilot study evaluating 16 MS patients and paroxysmal pain reached a mean treatment dosage of 154 mg daily. In this study, pregabalin demonstrated to be effective in reducing pain symptoms in almost 50% of patients [52]. In this study, three patients discontinued treatment because of adverse effects, in particular dizziness and general malaise. In another report on two patients, the occurrence of delirium, at a daily dose of 75 mg of pregabalin, was described. However, both patients were older than 60 and were also treated with specific CNS medications (benzodiazepine, baclofen, and/or tramadol) [53]. Thus, the Authors concluded that possible drug interactions particularly in older patients should be carefully considered. Moreover, in a recent, prospective, open-label, pilot study five patients with trigeminal neuralgia secondary to MS were successfully treated by a combination treatment of pregabalin plus lamotrigine [54]. Common adverse events possibly associated to pregabalin are weight gain, sleepiness, and fatigue, dizziness, leg swelling, disturbed vision, loss of coordination, and euphoria [55–57].
Pregabalin abuse among patients with opioid use disorders may increase the severity of withdrawal symptoms: a single-center, case-control study
Published in Psychiatry and Clinical Psychopharmacology, 2019
Özlem Çıtak Ekici, Volkan Şahiner, Gamze Erzin, Davut Ocak, Şafak Yalçın Şahiner, Erol Göka
There are studies in the literature showing that pregabalin abuse is present in patients with opioid dependence [24]. In addition to these data, there is a case report showing that pregabalin reduces opioid withdrawal symptoms, and findings reported that pregabalin is an effective, safe, and tolerable molecule for use in the treatment of opioid withdrawal symptoms [25,26]. In addition, the dose-dependent (100 and 200 mg doses) use of pregabalin in rats has been shown to reduce tolerance to the analgesic effect of morphine and opioid withdrawal symptoms induced by naloxone, and prevent morphine addiction [27]. There are also studies reporting that using high doses of pregabalin may cause withdrawal symptoms. Accompanied by these findings, although pregabalin is used as a self-medication to alleviate symptoms such as pain, restlessness, and anxiety by opioid users, it may negatively affect the existing opioid dependence. Related to that point, pregabalin itself might even have a distinct addictive potential [11].